v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Statement of Cash Flows [Abstract]    
Net loss $ (10,551,674) $ (6,150,372)
Adjustments to reconcile net loss to net cash used in operating activities:    
Changes in fair value of warrant liability 28,514 1,961
Commitment fee 250,000
Impairment on intangible assets 10,000
Interest expense 2,327,712 141,753
Settlement on note payable 1,178,000  
Conversion of debt to equity 448,802
Consulting fees 516,000
Stock-based compensation 1,565,212 2,649,573
Changes in operating assets and liabilities:    
Prepaid expenses (23,001) (90,230)
Accounts payable (19,079) (187,573)
Accrued expenses (879,938) 1,064,465
Tax payable (568,111)
Related party payable (31,000) (128,000)
Other Liabilities 60,022
Net cash used in operating activities (5,889,254) (2,946,512)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisition of drug license (123,497)
Net cash used in investing activities (123,497)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from convertible promissory note, net of issuance cost 2,150,000 2,077,000
Proceeds from sales of stocks and warrants, net 11,394,218 175,000
Proceeds from stock subscriptions 500,000
Proceeds from sale of preferred B shares 500,000
Payments on notes payable (2,730,182)
Payments for deferred financing costs (25,000)
Proceeds from FPA settlement 140,572
Payments on financed director and officer insurance (40,225)
Proceeds from At-the-Market sales of common shares 1,112,745
Proceeds from related party loans 100,000
Proceeds from shareholders 120,000
Payments to shareholders (120,000)
Merger proceeds net of transaction cost 778,942
Net cash provided by financing activities 13,002,128 3,130,942
NET CHANGE IN CASH 7,112,874 60,933
Cash - Beginning of period 63,741 2,808
Cash - End of period 7,176,615 63,741
SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES:    
Note payable settled with issuance of common stock 1,473,441 5,258,270
Interest payable settled with issuance of common stock 57,641 60,022
Reversal of OID 681,506
Repurchase of warrants 679,577
Issuance of warrants (679,577)
Discretionary non-cash payment to creditor with issuance of common stock 202 154,830
Conversion of Preferred B Shares to common stock (625)
Deemed dividend - warrant modification (1,530,910)
Non-cash equity payment for inducement fee on note payable 978,000
Non-cash directors’ and officers’ insurance 154,500
Non-cash PIPE Funds used for merger transaction close 2,950,000
Commitment fee paid in stock 250,000
Assumed income tax payable from merger 568,111
Assumed warrant liability from merger 22,525
Warrant conversion 96,200
SUPPLEMENTAL CASH FLOW INFORMATION:    
Interest Paid 79,153 2,460
Taxes Paid $ 551,593